New pill aims to keep leukemia away after transplant

NCT ID NCT07304232

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether the drug chidamide can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 134 adults with high-risk AML who are in remission after transplant will either take chidamide pills or receive standard observation. The study tracks how long patients stay cancer-free and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chidamide (a type of drug called a histone deacetylase inhibitor, taken as a pill)
What this could lead to: If successful, this could offer a new maintenance option to help prevent AML relapse after a stem cell transplant, potentially improving long-term survival.
What could go wrong: This is a mid-stage trial with only 134 participants, so results may not apply to all patients. Chidamide may cause side effects like fatigue or low blood counts, and it is not yet proven to extend survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) AML (ACUTE MYELOID LEUKEMIA)

Contacts and locations

Locations

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
The First Affiliated Hospital of Harbin Medical University
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150001, China
The Second Hospital of Hebei Medical University
NOT_YET_RECRUITING

Shijiazhuang, Hebei, 050000, China
Tianjin Medical University General Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Tianjin People's Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.